• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • 用户
  • 登录
  • 注册
  • 会员
  • 注销
  • 账号
  • 密码重置
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • 用户
  • 登录
  • 注册
  • 会员
  • 注销
  • 账号
  • 密码重置
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • clinical trial
  • Page 2
Etrasimod in the Management of Eosinophilic Oesophagitis: Promising Results from the VOYAGE Phase 2 Trial
Posted inClinical Updates Wellness & Lifestyle

Etrasimod in the Management of Eosinophilic Oesophagitis: Promising Results from the VOYAGE Phase 2 Trial

Posted by By MedXY 08/14/2025
The VOYAGE phase 2 trial demonstrated that etrasimod, an oral S1P receptor modulator, significantly reduces oesophageal eosinophilic inflammation and improves endoscopic findings in adults with eosinophilic oesophagitis, with a favorable safety profile over 52 weeks.
Read More
Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial
Posted inClinical Updates Wellness & Lifestyle

Exploring Combined Finerenone and Empagliflozin Therapy in CKD and Type 2 Diabetes: Baseline Insights from the CONFIDENCE Trial

Posted by By MedXY 08/13/2025
The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818 diverse participants.
Read More
Optimizing Hypertension Management Through Remote Monitoring: Insights from a Randomized Controlled Trial
Posted inClinical Updates Wellness & Lifestyle

Optimizing Hypertension Management Through Remote Monitoring: Insights from a Randomized Controlled Trial

Posted by By MedXY 08/11/2025
This study demonstrates the superior effectiveness of remote monitoring in reducing blood pressure among hypertensive patients compared to usual care and self-monitoring.
Read More
Dapagliflozin and Spironolactone: A Promising Combination for Heart Failure with Preserved Ejection Fraction
Posted inClinical Updates Wellness & Lifestyle

Dapagliflozin and Spironolactone: A Promising Combination for Heart Failure with Preserved Ejection Fraction

Posted by By MedXY 08/11/2025
The SOGALDI-PEF trial evaluates the effects of dapagliflozin combined with spironolactone versus dapagliflozin alone in patients with heart failure, revealing significant improvements in NT-proBNP levels and safety concerns.
Read More
Lorundrostat: A New Frontier in the Management of Uncontrolled and Treatment-Resistant Hypertension
Posted inClinical Updates Wellness & Lifestyle

Lorundrostat: A New Frontier in the Management of Uncontrolled and Treatment-Resistant Hypertension

Posted by By MedXY 08/09/2025
Lorundrostat, an aldosterone synthase inhibitor, significantly reduced systolic blood pressure in adults with uncontrolled and treatment-resistant hypertension, demonstrating efficacy and safety as an adjunct therapy.
Read More
Once-Weekly Insulin Efsitora: A Paradigm Shift in Initiation of Basal Insulin for Type 2 Diabetes
Posted inClinical Updates Wellness & Lifestyle

Once-Weekly Insulin Efsitora: A Paradigm Shift in Initiation of Basal Insulin for Type 2 Diabetes

Posted by By MedXY 08/09/2025
Weekly fixed-dose insulin efsitora demonstrated noninferiority to daily glargine in reducing HbA1c in insulin-naïve type 2 diabetes, with fewer hypoglycemic events and simpler dose adjustment.
Read More
Ashwagandha Supplementation for Cognitive Enhancement: Evidence from MCI and Healthy Populations
Posted inClinical Updates Wellness & Lifestyle

Ashwagandha Supplementation for Cognitive Enhancement: Evidence from MCI and Healthy Populations

Posted by By MedXY 08/09/2025
Recent randomized trials show ashwagandha, including Somin-On™, significantly improves memory and cognitive function in adults with mild cognitive impairment and healthy young adults, with good safety profiles.
Read More
Pomegranate Peel Extract: A Promising Adjunct in Non-Alcoholic Fatty Liver Disease Management?
Posted inClinical Updates Wellness & Lifestyle

Pomegranate Peel Extract: A Promising Adjunct in Non-Alcoholic Fatty Liver Disease Management?

Posted by By MedXY 08/08/2025
A double-blind RCT suggests pomegranate peel extract may improve liver enzymes, lipid profile, and inflammation in NAFLD patients, but does not significantly alter liver steatosis grade.
Read More
Flaxseed Powder Supplementation: Emerging Evidence in Non-Alcoholic Fatty Liver Disease and Metabolic Health
Posted inClinical Updates Wellness & Lifestyle

Flaxseed Powder Supplementation: Emerging Evidence in Non-Alcoholic Fatty Liver Disease and Metabolic Health

Posted by By MedXY 08/08/2025
Flaxseed powder supplementation shows promise in improving liver fat, lipid metabolism, and inflammation in NAFLD and related metabolic disorders, with effects on gut microbiota but limited synergism with fasting mimicking diets.
Read More
Mediterranean Diet Combined with Early Time-Restricted Feeding: A Promising Strategy for MASLD – Insights from the CHRONO-NAFLD Trial
Posted inClinical Updates Wellness & Lifestyle

Mediterranean Diet Combined with Early Time-Restricted Feeding: A Promising Strategy for MASLD – Insights from the CHRONO-NAFLD Trial

Posted by By MedXY 08/08/2025
A 12-week hypocaloric Mediterranean diet with early time-restricted feeding improved glycaemic control and cardiometabolic risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) compared to unrestricted timing or late time-restricted feeding.
Read More
Intermittent Fasting for Weight Loss in Night Shift Workers: A Three-Arm Superiority Randomised Clinical Trial
Posted inClinical Updates Wellness & Lifestyle

Intermittent Fasting for Weight Loss in Night Shift Workers: A Three-Arm Superiority Randomised Clinical Trial

Posted by By MedXY 08/08/2025
This clinical trial compared two modified intermittent fasting strategies to continuous energy restriction for weight loss and insulin resistance improvements in night shift workers, finding no significant differences but overall health benefits.
Read More
Intermittent Fasting in Overweight and Obese Postmenopausal Women with Rheumatoid Arthritis: Insights from a Randomized Controlled Trial
Posted inClinical Updates Wellness & Lifestyle

Intermittent Fasting in Overweight and Obese Postmenopausal Women with Rheumatoid Arthritis: Insights from a Randomized Controlled Trial

Posted by By MedXY 08/08/2025
A recent RCT suggests intermittent fasting may improve physical function and disease activity in overweight and obese postmenopausal women with RA, but shows no significant effect on inflammation or oxidative stress markers.
Read More
Clinical Advances in Akkermansia muciniphila-Based Interventions: Respiratory Symptom Relief, Muscle Strength Enhancement, and Obesity Management
Posted inClinical Updates Wellness & Lifestyle

Clinical Advances in Akkermansia muciniphila-Based Interventions: Respiratory Symptom Relief, Muscle Strength Enhancement, and Obesity Management

Posted by By MedXY 08/08/2025
Recent clinical trials reveal the therapeutic potential of Akkermansia muciniphila strains in alleviating respiratory symptoms, improving muscle strength, and preventing diet-induced obesity in dogs.
Read More
Intrathecal Autologous Bone Marrow Mononuclear Cell Therapy Plus Education: A Promising Approach for Autism Spectrum Disorder?
Posted inClinical Updates Wellness & Lifestyle

Intrathecal Autologous Bone Marrow Mononuclear Cell Therapy Plus Education: A Promising Approach for Autism Spectrum Disorder?

Posted by By MedXY 08/08/2025
A phase II trial finds that intrathecal autologous bone marrow mononuclear cell therapy combined with education significantly improves core symptoms and adaptive behaviors in young children with ASD compared to education alone.
Read More
Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial
Posted inClinical Updates Wellness & Lifestyle

Isatuximab On-Body Injector vs. Intravenous Administration in Relapsed/Refractory Multiple Myeloma: Insights from the Phase III IRAKLIA Trial

Posted by By MedXY 08/07/2025
The IRAKLIA Phase III trial found that subcutaneous isatuximab via on-body injector is noninferior to intravenous administration in efficacy and safety for relapsed/refractory multiple myeloma.
Read More
Olverembatinib Plus Venetoclax and Reduced-Intensity Chemotherapy: A Promising New Frontier for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Posted inClinical Updates Wellness & Lifestyle

Olverembatinib Plus Venetoclax and Reduced-Intensity Chemotherapy: A Promising New Frontier for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Posted by By MedXY 08/07/2025
A phase 2 trial shows that olverembatinib combined with venetoclax and reduced-intensity chemotherapy achieves high molecular response and survival rates in newly diagnosed Ph+ ALL patients, offering a less intensive alternative.
Read More
Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials
Posted inClinical Updates Wellness & Lifestyle

Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials

Posted by By MedXY 08/07/2025
The SURF trials found no significant difference in survival or recurrence-free outcomes between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting RFA as a less invasive, equally effective option.
Read More
Timing Matters: Sequential Pembrolizumab Plus Chemoradiation Outperforms Concurrent Approach in Locally Advanced Head and Neck Cancer
Posted inClinical Updates Wellness & Lifestyle

Timing Matters: Sequential Pembrolizumab Plus Chemoradiation Outperforms Concurrent Approach in Locally Advanced Head and Neck Cancer

Posted by By MedXY 08/07/2025
A Phase II trial finds sequential pembrolizumab after chemoradiation achieves superior locoregional control compared to concurrent administration in locally advanced head and neck squamous cell carcinoma.
Read More
Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials
Posted inClinical Updates Wellness & Lifestyle

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials

Posted by By MedXY 08/07/2025
The SURF trials found no significant difference in survival or recurrence between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting both as valid first-line options.
Read More
Addressing Sexual Dysfunction in HSCT Survivors: Efficacy of a Multimodal Intervention in a Randomised Clinical Trial
Posted inClinical Updates Wellness & Lifestyle

Addressing Sexual Dysfunction in HSCT Survivors: Efficacy of a Multimodal Intervention in a Randomised Clinical Trial

Posted by By MedXY 08/07/2025
A multimodal intervention significantly improved sexual satisfaction in hematopoietic stem-cell transplantation (HSCT) survivors compared to enhanced usual care, highlighting a promising approach for addressing sexual dysfunction in this population.
Read More
Testosterone Therapy in Middle-Aged and Older Men with Hypogonadism: Balancing Clinical Benefits and Risks
Posted inClinical Updates Wellness & Lifestyle

Testosterone Therapy in Middle-Aged and Older Men with Hypogonadism: Balancing Clinical Benefits and Risks

Posted by By MedXY 08/07/2025
Testosterone therapy offers modest benefits for sexual function, anemia, and bone health in older men with hypogonadism, but increases risks of venous thromboembolism, fractures, and arrhythmias. Careful patient selection and individualized risk-benefit assessment are essential.
Read More
Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival
Posted inClinical Updates Wellness & Lifestyle

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival

Posted by By MedXY 08/05/2025
The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and manageable safety.
Read More
Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial
Posted inClinical Updates Wellness & Lifestyle

Semaglutide Shows Promise in Type 1 Diabetes with Obesity: Insights from the ADJUST-T1D Trial

Posted by By MedXY 08/05/2025
Semaglutide significantly improved glycemic control and weight loss in adults with type 1 diabetes and obesity, without increasing major safety risks, according to the ADJUST-T1D trial.
Read More
Trehalose in ALS: No Efficacy Shown in the HEALEY ALS Platform Trial
Posted inClinical Updates Wellness & Lifestyle

Trehalose in ALS: No Efficacy Shown in the HEALEY ALS Platform Trial

Posted by By MedXY 08/03/2025
Trehalose was safe but did not slow ALS progression compared to placebo in a large, adaptive phase 2/3 trial.
Read More
EBIN Study: Sequencing Targeted Therapy and Immunotherapy in BRAFV600-Mutant Advanced Melanoma
Posted inClinical Updates Wellness & Lifestyle

EBIN Study: Sequencing Targeted Therapy and Immunotherapy in BRAFV600-Mutant Advanced Melanoma

Posted by By MedXY 08/03/2025
A phase 2 trial found that induction targeted therapy with encorafenib and binimetinib before immune checkpoint inhibitors did not improve progression-free survival versus immune checkpoint inhibitors alone in advanced melanoma with BRAFV600E/K mutations.
Read More
Oral Regimens for Whipple’s Disease: A Non-Inferiority Trial of Doxycycline-Hydroxychloroquine Versus Standard Intravenous Therapy
Posted inClinical Updates Wellness & Lifestyle

Oral Regimens for Whipple’s Disease: A Non-Inferiority Trial of Doxycycline-Hydroxychloroquine Versus Standard Intravenous Therapy

Posted by By MedXY 08/03/2025
A German phase 2/3 trial found oral doxycycline-hydroxychloroquine as effective and safe as standard intravenous ceftriaxone followed by oral trimethoprim-sulfamethoxazole for Whipple’s disease, potentially transforming outpatient management.
Read More
Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?
Posted inClinical Updates Wellness & Lifestyle

Relacorilant Plus Nab-Paclitaxel: A New Standard for Platinum-Resistant Ovarian Cancer?

Posted by By MedXY 08/03/2025
Relacorilant combined with nab-paclitaxel significantly improved progression-free and overall survival in platinum-resistant ovarian cancer, with a favorable safety profile, suggesting a potential new treatment standard.
Read More
Retifanlimab Plus Carboplatin-Paclitaxel: A New Standard for Advanced Squamous Cell Anal Cancer?
Posted inClinical Updates Wellness & Lifestyle

Retifanlimab Plus Carboplatin-Paclitaxel: A New Standard for Advanced Squamous Cell Anal Cancer?

Posted by By MedXY 08/03/2025
Retifanlimab combined with carboplatin-paclitaxel significantly prolongs progression-free survival in advanced squamous cell anal cancer, offering a promising new first-line standard of care.
Read More
Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial
Posted inClinical Updates Wellness & Lifestyle

Long-term Impact of Anifrolumab on Quality of Life in Systemic Lupus Erythematosus: Insights from the TULIP-LTE Trial

Posted by By MedXY 08/03/2025
A 4-year phase 3 extension study shows that anifrolumab improves patient-reported outcomes and quality of life in systemic lupus erythematosus, with a favorable safety profile.
Read More
Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia
Posted inClinical Updates Wellness & Lifestyle

Semaglutide for Weight Management in Clozapine-Treated Schizophrenia: Results from the COaST Phase 2 RCT in Australia

Posted by By MedXY 08/03/2025
Semaglutide significantly reduced body weight without impacting psychotic symptoms or clozapine levels in people with schizophrenia and obesity on clozapine therapy.
Read More

Posts pagination

Previous page 1 2 3 Next page
  • Timing Matters: Impact of Morning vs Afternoon High-Intensity Exercise on Inflammation and Glucose Control in Type 2 Diabetes
  • Nutritional Intervention in Chronic Heart Failure: Enhancing Functional Capacity and Nutritional Status without Major Clinical Outcome Impact
  • Prepregnancy Time-Restricted Eating and Exercise Training Do Not Improve Glycaemic Control in High-Risk Gestational Diabetes: Insights from the BEFORE THE BEGINNING Trial
  • 妊娠前の時間制限摂食と運動トレーニングが高リスクの妊娠糖尿病の血糖コントロールを改善しない: BEFORE THE BEGINNING試験からの洞察
  • Dynamic Effects of Short-Term Dietary Energy Loads on Fecal Serotonin, Gut Microbiome Tryptophanase, and Energy Absorption: Insights from a Randomized Crossover Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging AI Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular health cardiovascular risk clinical trial COVID-19 diabetes diet dinh dưỡng exercise health heart failure HFpEF Hypertension immunotherapy inflammation longevity mental health metformin Mortality NAFLD nutrition obesity Pregnancy prevention public health randomized controlled trial randomized trial semaglutide sexual health Suy Tim sức khỏe tim mạch TAVI thử nghiệm lâm sàng Trí tuệ nhân tạo type 2 diabetes weight loss wellness women's health 心力衰竭

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top